These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 28635741

  • 1. [A place of first-line drugs in treatment of multiple sclerosis].
    Kasatkin DS.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):145-151. PubMed ID: 28635741
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].
    Boyko AN, Alifirova VM.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):135-139. PubMed ID: 29265099
    [Abstract] [Full Text] [Related]

  • 5. Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?
    Sørensen PS.
    Nat Rev Neurol; 2016 Jan; 12(1):5-6. PubMed ID: 26635211
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
    Bell C, Anderson J, Ganguly T, Prescott J, Capila I, Lansing JC, Sachleben R, Iyer M, Fier I, Roach J, Storey K, Miller P, Hall S, Kantor D, Greenberg BM, Nair K, Glajch J.
    J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS.
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [Abstract] [Full Text] [Related]

  • 11. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
    Ziemssen T, Neuhaus O, Hohlfeld R.
    Drug Saf; 2001 Mar; 24(13):979-90. PubMed ID: 11735654
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
    Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, Kolodny S, Zivadinov R.
    Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
    [Abstract] [Full Text] [Related]

  • 13. Two decades of glatiramer acetate: From initial discovery to the current development of generics.
    Weinstock-Guttman B, Nair KV, Glajch JL, Ganguly TC, Kantor D.
    J Neurol Sci; 2017 May 15; 376():255-259. PubMed ID: 28431621
    [Abstract] [Full Text] [Related]

  • 14. Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.
    Ciplea AI, Kurzeja A, Thiel S, Haben S, Alexander J, Adamus E, Hellwig K.
    Mult Scler; 2022 Sep 15; 28(10):1641-1650. PubMed ID: 35362346
    [Abstract] [Full Text] [Related]

  • 15. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
    Meca-Lallana J, Hernández L, Caminero AB, Girón JM, Cano-Orgaz A, Carcelén-Gadea M, Muñoz D, Durán-Ferreras E, Martín-Hernández J, Sánchez-de la Rosa R, FATIGA Study Group.
    Eur Neurol; 2016 Sep 15; 76(1-2):40-7. PubMed ID: 27376845
    [Abstract] [Full Text] [Related]

  • 16. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
    Dhib-Jalbut S.
    Pharmacol Ther; 2003 May 15; 98(2):245-55. PubMed ID: 12725872
    [Abstract] [Full Text] [Related]

  • 17. Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection--a case report.
    Zecca C, Mainetti C, Blum R, Gobbi C.
    BMC Neurol; 2015 Dec 02; 15():249. PubMed ID: 26630967
    [Abstract] [Full Text] [Related]

  • 18. Safety evaluations of offspring breastfed by mothers receiving glatiramer acetate for relapsing multiple sclerosis.
    Ciplea AI, Kurzeja A, Thiel S, Haben S, Adamus E, Hellwig K.
    Mult Scler Relat Disord; 2023 Jul 02; 75():104771. PubMed ID: 37245349
    [Abstract] [Full Text] [Related]

  • 19. [The resolution of the expert body for the section on demyelinating diseases of the Russian Society of Neurologists and Russian Executive Committee of multiple sclerosis researchers (Kazan, 19 november 2015) on the 'Current principles and optimization of treatment of patients with relapsing-remitting multiple sclerosis with glatiramer acetate'].
    Redaktsiia.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016 Jul 02; 116(2 Pt 2):78-79. PubMed ID: 28635770
    [No Abstract] [Full Text] [Related]

  • 20. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B.
    Rev Neurol (Paris); 2008 Nov 02; 164(11):917-26. PubMed ID: 18790510
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.